Latest News
The latest and greatest from Flomics
Flomics Breakthrough in Liquid Biopsy: RNA & AI Enable Multicancer Early Detection
Flomics Biotech’s liquid biopsy breakthrough enables early detection of colorectal, lung, breast, prostate, and pancreatic cancers using cell.free RNA biomarkers and AI, achieving 92% predictive accuracy and 80% Stage I sensitivity, advancing toward clinical trials for…
Third face-to-face meeting of the LiquiDx project consortium
The consortium led by Flomics Biotech, in which the Biobank of the Andalusian Public Health System (SSPA) and Leitat Technological Center participate, held its second annual coordination meeting at the Parc de Recerca Biomèdica de…
First Freedom-to-operate study completed with the support of ACCIÓ
Flomics Biotech successfully completed a comprehensive Freedom-To-Operate (FTO) study in collaboration with ZBM Patents, confirming that its cfRNA-based liquid biopsy technology is free of patent conflicts. This milestone supports Flomics’ path to commercialization and strengthens its position for strategic European funding opportunities…
Successful Crowdfunding Campaign with Capital Cell
Flomics have officially closed our crowdfunding campaign with Capital Cell! Running from June 18 to July 12, 2024, this campaign has been a testament to the strong belief and support we have toward our mission, proposal, and work.
AGAUR Industrial PhD Grant to Giovanni Asole
‘’Tissue-of-origin deconvolution of the cell-free transcriptome for non-invasive screening of multiple cancer types’’ It is the project titled that has been awarded the AGAUR Industrial PhD Scholarship; Giovanni Asole project co-supervised by Dr. Julien Lagarde (head of bioinformatics…
Everything you wanted to know about cell-free RNA but were afraid to ask.
At Flomics, our research focuses on cfRNA and its potential as a powerful biomarker for early
disease detection. In this document, we address the most frequently asked questions about cfRNA, highlighting its
transformative impact on diagnostics and research. Most researchers and medical professionals are familiar with RNA, from messenger RNA (mRNA) which is crucial for protein synthesis to RNA vaccines that have combated COVID-19…
Flomics crowdfunding campaign with Capital Cell
Flomics just launched a crowdfunding campaign with Capital Cell, to support its validation studies on the early detection of different types of cancer, become a Flomics shareholder and Join us in the fight against cancer.
Flomics groundbreaking technology…
Flomics initial employee gets CumLaude PhD in Biomedicine from UPF
Lluc Cabús gets Cum Laude PhD in Biomedicine from UPF on the defence of his thesis, titled: “Analysis of circulating RNAs for the early detection of complex diseases using liquid biopsy.” Here are some of the notable conclusions:
Flomics welcomes the Illumina NextSeq 2000 machine to our sequencing toolkit!
Flomics has acquired the Illumina NextSeq 2000, a versatile machine known for its flexibility and efficiency. This acquisition marks a significant step forward in advancing next-generation sequencing…
Press
Flomics Newsletter
Stay up to date with Flomics news, get access to articles related to our services and don’t miss out on the most recent Biotech news and events.
Subscribe below: